荣昌生物(09995)周一股价大跌5.02%,引发市场关注。分析人士认为,虽然公司旗下抗体偶联药物维迪西妥单抗(RC48)新适应症取得重大进展,但公司整体财务和运营状况却令投资者感到忧虑,这可能是导致股价大跌的主因。
据野村证券最新研报显示,野村分析师上调荣昌生物未来两年的亏损预测,主要是由于公司产品销售上升带来的成本和费用增加,以及公司现金燃烧状况导致利息支出上升所致。报告认为,荣昌生物目前或需进一步控制运营支出。
与此同时,荣昌生物当前最为看好的候选药物RC48日前获得新适应症上市申请获受理并纳入优先审评程序,这一利好消息在一定程度上缓解了公司运营状况的担忧。但分析指出,新产品上市依然需要时日,短期内难以扭转公司整体亏损状况。综合来看,公司运营前景依旧存有不确定性,这可能是导致投资者做出了抛售选择的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.